Introduction
, the causative agent of infectious mononucleosis (Henle & Henle, 1979) , has been associated with Burkitt's lymphoma (Epstein & Achong, 1979) and nasopharyngeal carcinoma (Klein, 1979) . The EBV major membrane antigen (MA), gp350, is a strong candidate for a subunit vaccine since it has been shown to induce specific in vitro virus-neutralizing antibody (Epstein et al., 1985 (Epstein et al., , 1986 Morgan et al., 1984; North et al., 1982; Qualtiere et al., 1982; Thorley-Lawson, 1979; Thorley-Lawson & Poodry, 1982) , antibody-dependent cellular cytotoxicity (ADCC) (Qualtiere et al., 1982) , and T cell-mediated responses (Ulaeto et al., 1988; Bejarano et al., 1990; Wallace et al., 1991) . gp350 has been identified as the virus protein that interacts with B lymphocytes (Wells et al., 1982; Tanner et al., 1988) by binding to the C3d cell receptor (Fingeroth et al., 1984; Nemerow et al., 1985 Nemerow et al., , 1989 .
The gp350 is encoded by the BamHI L fragment of EBV in the BL-LF1 reading frame (Biggen et al., 1984) as a 907 amino acid (aa) protein containing 37 putative N-glycosylation sites (Beisel et al., 1985) . A smaller related protein (gp220) encoded by the same gene (Hummel et al., 1984; Beisel et al., 1985) is produced by splicing, resulting in an in-frame deletion of aa 502 to 698 (Tanner et al., 1988) . Both proteins are heavily glycosylated with > 50 % of their M r due to carbohydrate (Edson & Thorley-Lawson, 1983) . Oligosaccharides on gp350 are both N-and O-linked (Serafini-Cessi et al., 1989; Gong & Kieff, 1990) and glycosylation is blocked by tunicamycin (Edson & Thorley-Lawson, 1981 Strnad et al., 1983) .
Recombinant EBV gp350 has been expressed in a variety of systems, including Escherichia coli (Beisel et aI., 1985; Zhang et al., 1991; Pither et al., 1992a, b) , yeast (Schultz et al., 1987; Emini et al., 1988) , mammalian cells Emini et al., 1988) and viral vectors (Mackett & Arrand, 1985; Lowe et al., 1987; Conway et al., 1989; Ragot et al., 1993) . The ability of these recombinant proteins to induce antibodies in animals capable of in vitro virus neutralization has been extremely variable; for example, recombinant antigens produced in E. coli and yeast have demonstrated relatively poor ability to induce neutralizing antibodies (Beisel et al., 1985; Schultz et aL, 1987; Emini et al., P.-f. Zhang and C. J. Marcus-Sekura 1988; Zhang et al., 1991) . Candidate gp350 vaccines from EBV-producing cells (Epstein et al., 1985 (Epstein et al., , 1986 have varied in their ability to induce protective immunity to EBV in a cottontop tamarin model, even though these preparations elicited antibodies effective in in vitro virus neutralization (Epstein et al., 1986) . Variability in the ability of gp350 preparations to induce neutralizing antibodies or protection has been attributed to alterations in glycosylation or protein conformation which may alter the availability of epitopes to the immune system (Emini et at., 1988; Beisel et at., 1985; Epstein et al., 1986) . A recombinant gp350 expressed in a bovine papitlomavirus vector (Finerty et al., 1992) has recently been shown to induce protective immunity in the tamarin model.
Several investigators have produced monoclonal antibodies (MAbs) with specificity for EBV gp350, including MAbs that have in vitro virus neutralizing activity (Hoffman et al., 1980; Qualtiere et al., 1982 Qualtiere et al., , 1987 Thorley-Lawson & Geilinger, 1980) . In order to map critical epitopes on gp350 including the neutralizing epitope(s), we have previously expressed overlapping portions of gp350 in an E. coli expression system and analysed the ability of a panel of 14 MAbs to react with the recombinant proteins (Zhang et al., 1991) . Thirteen of the 14 MAbs had previously been assigned to seven groups (I to VII) by competition experiments (Qualtiere et al., 1987) . The additional MAb was generated against a recombinant fragment of gp350 expressed in E. coli (Beisel et aL, 1985) . Three of the 14 MAbs reacted with the protein fragments, defining three epitopes (aa 310 to 325, aa 326 to 439 and aa 733 to 841). However, most of the MAbs (including a neutralizing MAb) were unreactive with any of the E. col#expressed proteins, although 92 % of the amino acid sequence of gp350 (all but the N terminus) was represented. Either all the missing epitopes were in the N-terminal 8 % of the protein or, more likely, specific glycosylation or conformation is necessary for antibody recognition. To evaluate these possibilities, we have now expressed full-length gp350 and five subgenomic polypeptides encompassing all of gp350 in a baculovirus vector. The baculovirus expression system has been used to express a variety of proteins in insect cells. Proteins produced using this system often retain function and signal sequences, glycosylation sites and proteolytic cleavage sites have been authentically recognized (Luckow & Summers, 1988) . Recombinant proteins are both N-and O-glycosylated, although conversion of high mannose to complex N-linked oligosaccharides does not occur (Luckow & Summers, 1988) . Using these baculovirus-expressed recombinant gp350 proteins and the same panel of MAbs (Qualtiere et al., 1987; Beisel et al., 1985) we have further characterized epitopes on gp350.
Methods
Cells and virus. Sf9 (fall armyworm ovary, Spodoptera fi'ugiperda) cells (ATCCCRL1711) were cultured at 27°C in IPL-41 medium containing 2% tryptose phosphate broth, 1% amphotericin B, 0.1% gentamicin and 10% heat-inactivated fetal bovine serum (all from Gibco). Sf9 cells were split 1 : 5 weekly. Autographica californica nuclear polyhedrosis virus (AcNPV) was obtained by transfection of Sf9 cells with AcNPV DNA (Invitrogen) and titrated as described (Summers & Smith, 1987) . Sf9 cells were infected with virus (m.o.i. 5 p.f.u./cell) and harvested 72 h post-infection.
Antibodies. MAbs (F30-3C2-C11, F29-167-A10, F34-IF2, F34-6B5-A2, 2F5.6, F16-3E3, F29-89, F16-11B7, F16-1C10, F34-5H7, F34-2Bt 1, F34-1DS, F30-3F12) to EBV gp350, raised against purified virus or whole cell preparations after induction (Qualtiere et aL, 1987) , were provided by L. Qualtiere and used at 1 : 100 dilution. MAb BMA-17, raised against a bacterially expressed antigen III57 encoded by nucleotides (nt) 3611 to 2083 in EBV BamHI L (Beisel et al., 1985) , was a gift from G. Pearson and was used at 1 : 1000 dilution. MAb 14C4 was generated against poliovirus (Singer et al., 1989) , and used at 1 : 100 dilution. Rabbit antisera to portions of EBV gp350, anti-E4 and anti-E203, raised against E. coil-expressed antigens E4 and E203 encoded by nt 2307 to 1782 and 4287 to 2301 in EBV BamHI L respectively (Zhang et aL, 1991) , were pooled 1 : 1 to produce a mixture of antibodies to 92 % of the gp350 amino acid sequence, and used at 1 : 100 dilution. A human EBV-positive serum reactive with membrane antigen (gp350) was provided by G. Armstrong and used at 1 : 50 dilution.
Construction of recombinant viruses. Fragments containing nucleotides coding for gp350 were generated using the PCR (Mullis & Faloona, 1987 ) from a plasmid (0.5 gg) containing the EBV BamHI L fragment in pBR322 which had been subcloned from a plasmid containing the EBV BamHI L, w and b fragments, kindly provided by B. Griffin (Arrand et al., 1981) . Primers with start and stop codons (bold), and restriction enzyme sites (underlined) were designed based on the nucleotide sequence of EBV gp350 BamHI L (B95-8 strain) (Biggin et aL, 1984) . Primer pairs (denoted by subscripts 1 and 2, where 1 is the coding strand and 2 is the complementary strand) were synthesized using a Milligen 8700 DNA synthesizer (MitliGen/ Biosearch). Numbers in parentheses indicate inclusive nucleotides in the BamHI L fragment in each primer and their locations are indicated with asterisks. For generation of fragments for clones P1 (4504 to 3752), P2 (4129 to 3380), P3 (3751 to 3005), P4 (3004 to 2255) and P5 (2254 to 1784), five PCR reactions for each fragment were performed using 40 cycles of amplification (94 °C, 2 min; 55 °C, 2 rain; 70 °C, 4 rain), and PCR products were purified from 2-7 % agarose gels (2 % NuSieve, 0.7 % Seakem FMC) by electroelution. For construction of P6 (4504 to 1784), the PCR reactions were performed using 35 cycles of amplification (94 °C, 1 rain; 60 °C, 2 min; 72 °C, 10 rain), and PCR products were purified from 0.7 % agarose gels (Bio-Rad) by electroelution. The gelpurified PCR fragments were characterized by restriction enzyme digestion.
Transfer vector DNA (pVLI393) (Invitrogen) and the fragments coding for gp350 were digested with appropriate restriction enzymes, ligated and transfected into competent E. eoli DH5-~ bacteria (BRL), and ampicilliu-resistant colonies were screened by restriction enzyme digestion.
Purified plasmids containing inserts were characterized by restriction enzyme digestion, co-transfected with wild-type baculovirus (AcNPV) (Summers & Smith, 1987) , and screened for recombinant viruses by several rounds of limiting dilution. Virus-containing supernatants were harvested 7 days post-infection, and transferred into a duplicate 96-well plate. Cells in the original plate were lysed by adding 200 gl/weU of 0-5 M-NaOH, and lysates were neutralized by adding 20 gl/well of 10 M-ammonium acetate. Cell lysates were spotted onto nitrocellulose and hybridizations were performed with non-radioactive DNA probes labelled using the GENIUS detection kit (Boehringer). To characterize the gp350 DNA fragments in the context of the recombinant viruses, infected cells were resuspended in K buffer (10 mM-Tris HC1 pH 8.2, 50 mM-KC1, 1.5 mM-MgCI~, 0.5 % Tween-20, 100 gg/ml proteinase K). Samples were incubated at 56 °C for 45 rain, extracted with phenol and chloroform, precipitated with ethanol, resuspended in 10 mM-Tris-HC1, 1 mM-EDTA, pH 8.0 (Kawasaki, 1990) , and PCR was performed as described above with primers used for generation of the EBV gp350 fragments. The PCR products were further characterized by restriction enzyme digestion.
Expression of recombinant proteins. Cells infected in a 96-well plate were lysed 72 h post-infection with 200 gt lysis buffer A [0.02 MTris-HC1 pH 7"4, 0"15 M-NaCI, 0.001 M-PMSF, 0.012 M-sodium deoxycholate, 0"007% 2-mercaptoethanol (2-ME), 0.5 % NP40], and a dot blot immunoassay was performed (Zhang et al., 1991) . Alternatively, cell pellets were diluted in PBS followed by addition of 1/5 volume of SDS-PAGE sample buffer (0.06 ta-Tris-HCl pH 6.8, 10% glycerol, 2 % SDS, 0.13 % bromophenol blue and 5 % 2-ME), and Western blot analysis was performed as described previously (Marcus-Sekura et al., 1990 ) using 14 % gels for P1, P2, P3, P4 and P5 and 8 % gels for P6. For analysis with MAbs by dot blot immunoassay, infected cells were lysed with buffer A, sonicated and centrifuged (27000g, 30min, 4°C). Sonicated supernatant, diluted in PBS to produce an A~s 0 of 0-5, was analysed by dot blot immunoassay (100 gl/well).
Fractionation of Sf 9 cells expressing recombinant proteins.
Infected Sf9 cells were washed with cold Ca2+/Mg2+-free PBS pH7.2, resuspended in lysis buffer B (20 mM-Tris-HC1 pH 7.5, 1 mM-EGTA, 1 mM-MgCI2, 1 mM-DTT, containing the protease inhibitors leupeptin, aprotinin, and pepstatin, each at 0.1 gg/ml, and 2 mM-PMSF), and broken by 20 to 30 passages through a 25-gauge needle. Unbroken cells were removed by low-speed ceutrifugation, and the supernatant was centrifuged at 100000 g for 60 rain at 4 °C to separate the cytosolic fraction (supernatant) from the membrane fraction (pellet). The pellet was solubilized in buffer C (20 mM-Tris-HCl pH 7-5, 1 mM-EGTA, 1 mM-EDTA, 1 mM-DTT, 1% Triton X-100, containing the same concentrations of protease inhibitors as in lysis buffer B), sonicated and centrifuged at 100000g for 60min at 4 °C. The supernatants contained the solubilized membrane fraction.
Detection ofglycoproteins using glycosidase. The cell pellet (1 gl) was resuspended in 100gl buffer F (50mM-Tris-HCl pH 8-6, 25mM-EDTA, 1% Triton X-100, 1% 2-ME and 0.2% SDS) (Vialard et al., 1990) , and 2 units peptide-N-glycosidase F (PNGase F) (Boehringer) was added. For each protein, duplicate samples with or without PNGase F were incubated at 37 °C overnight, precipitated with ethanol (Vialard et al., 1990) , resuspended in PBS, and a Western blot was performed. For dot blot analysis, membrane fractions of P6 (3 ml) were incubated at 37 °C overnight in buffer F with or without 50 units PNGase F. A sample was analysed by Western blot for complete digestion, and the remaining material was used for dot blot immunoassay (300 gl/well).
Results

Construction of recombinant baculoviruses
To produce recombinant baculoviruses expressing the entire gp350 coding sequence and subgenomic fragments ofgp350 (Fig. 1) , a series of recombinant transfer vectors was generated using the transfer vector pVL1393, which was chosen since it produces non-fusion proteins. Fragments containing portions of, or the entire gp350 coding sequence were generated by PCR using a plasmid containing EBV BamHI L as template, and recombinant transfer vectors were obtained by ligation and transformation into bacteria. Sf9 cells were co-transfected with the recombinant transfer vectors and wild-type virus (AcNPV) DNA, and six recombinant viruses were isolated by limiting dilution and hybridization. To confirm the presence of EBV fragments in these recombinant viruses, DNA was extracted from infected Sf9 cells, PCR was performed using the primers used to generate the initial gp350 fragments, and PCR products were characterized by restriction enzyme digestion. The results indicated that the inserts were the correct size and contained the predicted restriction sites.
Expression of EBV gp350 proteins in Sf9 cells
Dot blot immunoassays were performed with lysates obtained from Sf9 cells infected with the six recombinant viruses using an EBV gp350-positive human serum (Fig.  2a) . All six cell lysates reacted with the human serum, indicating that all recombinant viruses expressed gp350.
Lysates from P6 produced the strongest reaction, probably reflecting the fact that full-length gp350 contains more epitopes than the protein fragments from P1 to P5. All six cell lysates also reacted on dot blots with pooled rabbit sera to gp350 (data not shown). To determine the size of the recombinant proteins, infected cells were analysed by Western blot. All six proteins reacted with pooled rabbit antisera to gp350 on Western blots ( Fig. 2b and c) . The Mrs of the recombinant proteins (dots in Fig. 2b and c) calculated using linear regression analysis based on migration of the M r markers were 37K (P1), 32K (P2), 34K (P3), 33K (P4), 19K (P5) (Fig. 2 b) and 134K (P6) (Fig. 2 c) . These were compared with the Mrs predicted from the number of amino acids (using 0.1K per amino acid) of 25K Fig. 3 b, lanes 1 and 2). Since no immunoreactive bands were detected in preparations infected with AcNPV, these bands may be fragments of gp350. Preliminary data suggest these faster migrating species are present over a period from 48 to 116 h post-infection, suggesting they may represent translation rather than degradation products.
Analysis of recombinant proteins for glycosylation
The recombinant proteins produced in the Sf9 cells were treated with PNGase F, an enzyme that hydrolyses all classes of asparagine-linked glycans, high-mannose, hybrid, and bi-, tri-and tetra-antennary oligosaccharides (Tarentino et al., 1985) , and analysed by Western blotting (Fig. 3) . For the protein produced by P1, the M r changed from 37K prior to treatment (Fig. 3a , lane 1) to 26K after treatment (Fig. 3a, lane 2) . For the protein produced by P6, the Mr changed from 134K prior to treatment (Fig. 3c , lane 1) to 91K after treatment (Fig.  3 c, lane 2) . The Mrs of the proteins produced by P2, P3, P4 and P5 did not change after treatment (Fig. 3 a, lanes 3 to 6; Fig. 3b , lanes 1 to 4). This indicates that both P1 and P6 produce glycosylated proteins with approximately 30% of their apparent Mr being N-linked oligosaccharide. Since the Mrs of the proteins from P1 (26K) and P6 (91K) after removal of carbohydrate with PNGase F are very close to the predicted Mrs (25K for P1 and 90.7K for P6) as calculated based on the number of amino acids, these proteins probably contain predominantly N-linked sugar residues. Native gp350 contains both N-linked and O-linked sugars, both of which contribute to the Mr resulting in more than 50 % of the apparent Mr being oligosaccharide (Edson & ThorleyLawson, 1983; Serafini-Cessi et al., 1989) .
Reactivity of recombinant gp350 polypeptides with monoclonal antibodies
Using the recombinant proteins expressed in baculovirus and MAbs used previously for epitope mapping with subgenomic fragments of gp350 expressed in E. coli (Zhang et al., 1991) , dot blot immunoassays were performed (Fig. 4) . All the MAbs were reactive with fulllength recombinant gp350 from P6 (row F) indicating that the full-length baculovirus-expressed glycoprotein contains epitopes recognized by all of the MAbs. However, only four of the 14 MAbs reacted with the subgenomic fragments. Two MAbs, F34-5H7 (column 10) and F34-2BI 1 (column 11) recognized P3; one MAb, F29-89 (column 7) recognized PS; one MAb, BMA-17 (column 14) recognized P2 and P3. MAb 2F5.6 reacted strongly only with the protein from P6; it exhibited nonspecific binding to the other preparations (column 5). The observed reactivity was entirely consistent with that previously seen with the E. col#expressed fragments of gp350 (Zhang et al., 1991) . Based on the reactivity of the recombinant proteins with the MAbs, no additional epitopes on gp350 could be identified. However, two of the three previously identified epitopes could be more precisely defined as encompassing nt 1980 to 2254 (aa 841 to 750) for epitope I, and nt 3186 to 3379 (aa 439 to 376) for epitope II; epitope Ill, nt 3528 to 3576 (aa 325 to 310) remained unchanged. Since P1 contains 8% of the genome not previously expressed in E. coli, the data indicate that none of the MAbs recognize linear epitopes in this N-terminal region; and furthermore, since P1 is glycosylated, this glycosylation does not result in recognition of the P1 fragment. The virus-neutralizing MAb, F29-167-A10 (Fig. 4 , column 2), and MAbs F30-3C2-C11, F34-1F2, F34-6B5-A2, F16-3E3, F16-11B7, F16-1C10, F34-1D8 and F30-3F12 only recognized protein from P6. To determine whether the recognition by these MAbs reactive only with protein from P6 is glycosylation-or conformationdependent, full-length protein expressed by P6 was digested with the PNGase F, and dot blots with 10 of the 14 MAbs were repeated. None of the MAbs tested (BMA-17, F29-167-A10, F34-1D8, FI6-3E3, 2F5.6, F34-6B5-A2, F34-1F2, F30-3C2-Cll, F29-89, F16-1C10), including eight of those which were unreactive with E. coli and baculovirus-expressed gp350 protein fragments, exhibited differences in reactivity with the P6 protein before and after digestion with PNGase F (data not shown).
In order to assess directly whether recognition by the neutralizing MAb and other MAbs unreactive with the protein fragments is conformation-dependent, full-length recombinant gp350 from P6 was analysed with the 14 MAbs using Western blotting (Fig. 5) . All but three of the MAbs, F34-5H7 (lane 10), F34-2Bll (lane 11) and BMA-17 (lane 14), lost reactivity. MAbs that lost reactivity included all the MAbs which were unreactive with E. col# and baculovirus-expressed protein fragments, including the neutralizing MAb F29-167-A10 (Fig. 5, lane 2) . The three MAbs that retained reactivity on Western blots also reacted with E. cot#expressed and baculovirus-expressed gp350 subgenomic protein fragments. One MAb, F29-89, which was reactive with the polypeptide fragments expressed by E4 and E9 (in E. coli) (Zhang et al., 1991) and P5 (in baculovirus) by dot blot immunoassay (Fig. 4, column 7) , was unreactive on Western blots (Fig. 5, lane 7) . Since preparation of proteins for SDS-PAGE involves addition of sample buffer containing SDS and 2-ME followed by boiling, a dot blot was performed in which protein from P6 was denatured by adding SDS-PAGE sample buffer, and either incubated for 10 min at room temperature or boiled for 10 min prior to application onto nitrocellulose. Addition of SDS and 2-ME resulting in a final concentration of 0-4 % SDS, 1% 2-ME was sufficient to produce loss of reactivity with four MAbs [F29-167-A10, F34-1F2 and F16-1C10 (which were only reactive with full-length protein produced by P6), and F29-89 (which was reactive with E. col#expressed gp350 fragments E4 and E9 on dot blots and with baculovirus-expressed polypeptide from P5 on dot blots but not Western blots)] with results identical to those produced by subsequent boiling of the samples. No loss in reactivity with denatured protein from P6 was observed with BMA-17 and F34-5H7 (data not shown).
Discussion
Attempts to produce EBV vaccines have focused on subunit vaccines containing the virus major MA. The MA glycoprotein gp350 induces antibodies capable of neutralizing virus infectivity in vitro, as well as ADCC and T cell-mediated responses. An elegant animal model, based on the cottontop tamarin, has been developed (Morgan et al., 1984; Epstein et al., 1985) . Whereas some preparations of gp350 have been protective against EBVinduced lymphomas in the tamarin model, other preparations reactive to neutralizing antibodies in vitro have not been uniformly protective in the animal model (Epstein et al., 1986) . Protective immunity has been induced with denatured gp350 after renaturation and removal of SDS, and can be achieved in the absence of virus-neutralizing antibody and even in the apparent absence of any antibody to gp350. This suggests that additional factors are involved in induction of protective immunity by gp350, and indicates that in vitro tests other than measurement of reactivity with or ability to induce neutralizing antibodies may be required to assess the potency of vaccine preparations.
Identification of requirements for recognition of gp350 in vitro might eventually allow selection of MAbs whose recognition correlates with the ability of a particular gp350 preparation to induce protection. We have begun to develop such in vitro assays by assessing the reactivity of gp350 preparations with a panel of 14 MAbs. Thirteen of these MAbs, including one which is virus-neutralizing in vitro, have previously been shown by competition experiments to react with seven different epitopes on gp350 (Qualtiere et at., 1987) (groups I to VII). The fourteenth MAb, BMA-17, reacts with E. col#expressed polypeptides in a manner different from the other seven groups (Zhang et al., 1991) . In dot blot immunoassays, recombinant gp350 polypeptides expressed in E. coli reacted with four of 14 MAbs (representing competition groups IV, VI and VIII) defining three epitopes (Zhang et al., 1991) . Based on the reactivities of baculovirusexpressed gp350 polypeptides, we have now defined these epitopes more precisely as encompassing aa 841 to 750 for epitope I, aa 439 to 376 for epitope II, and aa 325 to 310 for epitope III. Pither et al. (1992a) have used bacterially expressed fusion proteins to identify regions on gp350 recognized by human sera. Two of the Cterminal regions they identified (764 to 869 and 352 to 425) may correspond to our epitopes I at 750 to 841 and II at 326 to 439. Using peptides (Pither et al., 1992b) , they have identified linear epitopes including an epitope(s) in the region 301 to 315 and 313 to 327 which is close to epitope III at 310 to 325 recognized by BMA-17.
In the dot blot immunoassay, the E. coli-expressed polypeptides reacted with only four of the 14 MAbs examined, yet gp350 isolated from EBV-infected B95-8 cells was reactive with all 14 MAbs. Since 92 % of the gp350 amino acid sequence was represented in the protein fragments tested, either the epitopes recognized by the 10 unreactive MAbs (one of which was the neutralizing MAb) were located in the 8 % of the protein that was not expressed, or additional factors such as glycosylation or conformational requirements were necessary for recognition by the MAbs. To examine possibilities, the entire gp350 protein as well as five polypeptides encompassing the entire gp350 amino acid sequence were expressed in a baculovirus expression system. Proteins expressed by all six clones reacted with a human EBV-positive serum in a dot blot immunoassay, indicating that humans produce antibodies capable of reacting with epitopes present in all five regions of gp350. Since all the cloned polypeptides also reacted with pooled rabbit antisera generated against the 92 % of the gp350 amino acid sequence expressed in E. coli, the E. col#expressed polypeptides must contain epitopes capable of inducing antibodies to all five regions. Protein expressed by P1 (amino acids 1 to 251) reacted with the pooled rabbit antisera generated against polypeptides missing aa 1 to 73 of gp350, indicating that an epitope must be present in P1 between aa 74 and 251. Since the pooled rabbit serum was positive on Western blots with proteins produced by all five subclones, the epitopes recognized by the rabbit antisera are present even in denatured polypeptides. Pither et al. (1992b) have also identified several linear epitopes in the N-terminal region reactive with peptides. The P1 polypeptide (which contains the 8 % of the protein not previously expressed in E. coli; aa 1 to 73 encoded by nt 4504 to 4286) did not react with any additional MAbs, indicating that the failure of 10 of the MAbs to react with the bacterially expressed proteins cannot be attributed solely to the absence of aa 1 to 73. Furthermore, glycosylation of the P1 fragment is insufficient for recognition by any of the MAbs.
The full-length protein from P6 was recognized in dot blot immunoassays by all 14 MAbs, including the neutralizing MAb, and did not lose reactivity with any of the 10 MAbs examined when it was deglycosylated in vitro and analysed by dot blot immunoassay. (This group of 10 MAbs included eight of the MAbs unreactive with E. coli-expressed polypeptides and was chosen to include representatives from each of Qualtiere's competition groups I to VII except for group VI, since both group VI MAbs were reactive with E. coli fragments.) However, the P6 protein did lose reactivity with 11 of the 14 MAbs when it was incubated with SDS/2-ME in preparation for SDS-PAGE and analysed by Western blotting, and with four of six MAbs tested when it was incubated with SDS/2-ME with or without boiling prior to dot blotting. This suggests that recognition by the MAbs that lost reactivity (representing Qualtiere's competition groups I to V and VII) is conformation-dependent.
The role of glycosylation is more difficult to assess. P1 and P6 were glycosylated and P2, P3, P4 and P5 were not, presumably reflecting the presence of a signal sequence on both the P1 and P6 proteins capable of directing these proteins to the endoplasmic reticulum where the glycosylating system is localized (Kornfeld & Kornfeld, 1985) . Since all the MAbs recognized enzymatically deglycosylated protein from P6, recognition does not appear to require a glycosylated protein. However, the data do not allow us to rule out the possibility that cotranslational glycosylation is required for proper folding, and therefore glycosylation indirectly contributes to recognition through its effects on folding.
The panel of MAbs which we have analysed appears to comprise antibodies with three types of recognition requirements: MAbs that recognize strictly linear epitopes (BMA-17, F34-2Bll, F34-5H7), evidenced by reactivity with both E. coli-and baculovirus-expressed polypeptides and by reactivity on both Western blots and dot blots with denatured protein; a MAb requiring some localized folding (F29-89) characterized by reactivity with undenatured subgenomic fragments on dot blots, but not with denatured protein either on Western blot or dot blot immunoassay; and MAbs requiring longdistance folding for recognition (F29-167-A10, F34-1F2, F16-1C10, F30-3C2-C11, F34-6B5-A2, 2F5.6, F16-3E3, F 16-11B7, F34-D8, F30-3F2) characterized by reactivity only with a large or full-length undenatured protein in a dot blot immunoassay. This last group includes the neutralizing MAb, F29-167-A10. Twelve of the MAbs did not require a glycosylated P6 protein for recognition (two, F16-11B7 and F30-3F12, were not evaluated). Since all of the MAbs examined were mouse MAbs, it would be of interest to analyse human antibodies which might display different patterns of reactivity.
It seems likely that subtle changes in conformation may alter the ability of the gp350 immunogen to induce protective immunity. We have demonstrated here that one possible way to assess such subtle changes may be to P.-f. Zhang and C. J. Marcus-Sekura evaluate the ability of preparations of gp350 to react with panels of MAbs that are sensitive to conformational changes. For future vaccine development, it may be possible to identify a panel of MAbs capable of distinguishing between preparations that protect and those which are ineffective in the tamarin model, and to use these MAbs to analyse the potency of vaccine preparations.
